<!DOCTYPE html>
<html class="theme-sleek astro-STCLZLJ5" lang="en">
  <head>
    <!-- Global Metadata -->
    <meta charset="utf-8">
    <meta name="viewport" content="width=device-width,initial-scale=1">
    <meta name="theme-color" media="(prefers-color-scheme: light)" content="#ffffff">
<meta name="theme-color" media="(prefers-color-scheme: dark)" content="#18181b">
<!-- 
  This is an example. 
  Use https://realfavicongenerator.net to generate the icons and manifest. 
-->
<link href="/favicon.ico" rel="shortcut icon">

    <!-- Primary Meta Tags --><title>CBD-enriched medical cannabis for intractable pediatric epilepsy: The current Israeli experience.</title>
<meta name="title" content="CBD-enriched medical cannabis for intractable pediatric epilepsy: The current Israeli experience.">
<meta name="description" content="Medical Cannabis Awareness New Zealand">


<!-- Open Graph / Facebook -->
<meta property="og:title" content="CBD-enriched medical cannabis for intractable pediatric epilepsy: The current Israeli experience.">
<meta property="og:description" content="Medical Cannabis Awareness New Zealand">
<meta property="og:type" content="article">
<meta property="og:url" content="https://mcanz.org.nz/blog/cbd-intractable-pediatric-epilepsy">

<meta property="article:published_time" content="2016-02-11T00:00:00.000Z">





<!-- Twitter -->
<meta property="twitter:title" content="CBD-enriched medical cannabis for intractable pediatric epilepsy: The current Israeli experience.">
<meta property="twitter:description" content="Medical Cannabis Awareness New Zealand">


<meta property="twitter:card" content="summary_large_image">


<!-- {twitter.url && <meta property="twitter:url" content={twitter.url} />} -->

  <link rel="stylesheet" href="/assets/_slug_.2607fc28.css" />
<link rel="stylesheet" href="/assets/_slug_.f022e152.css" /></head>

  <body class="text-text-body bg-bg-body max-w-3xl mx-auto px-4 sm:px-8 astro-STCLZLJ5">
    <header class="astro-FAM4J5CX">
  <a class="skip-to-main astro-FAM4J5CX" href="#main"> Skip to content</a>
  <nav class="astro-FAM4J5CX">
    <section class="astro-FAM4J5CX">
      <ul class="astro-FAM4J5CX">
        <li class="astro-FAM4J5CX"><!-- DO NOT FORMAT. IT ADDS AN EXTRA SPACE ON RENDERED CONTENT. --><a href="/" class="astro-FAM4J5CX header-link unset animated gradient-colors astro-C675TBRQ">Home</a>
</li>
        <li class="astro-FAM4J5CX"><!-- DO NOT FORMAT. IT ADDS AN EXTRA SPACE ON RENDERED CONTENT. --><a href="/blog" class="astro-FAM4J5CX active header-link unset animated gradient-colors astro-C675TBRQ">Blog</a>
</li>
      </ul>
    </section>
  </nav>
</header>

    <main id="main" class="astro-STCLZLJ5">
      <section class="blog-post astro-STCLZLJ5">
        <h1 class="title astro-STCLZLJ5">CBD-enriched medical cannabis for intractable pediatric epilepsy: The current Israeli experience.</h1>
        <time class="publish-date astro-STCLZLJ5">Feb 11, 2016</time>
        <article><p>Authors <a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=Tzadok%20M%5BAuthor%5D&#38;cauthor=true&#38;cauthor_uid=26800377">Tzadok M</a>, <a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=Uliel-Siboni%20S%5BAuthor%5D&#38;cauthor=true&#38;cauthor_uid=26800377">Uliel-Siboni S</a>, <a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=Linder%20I%5BAuthor%5D&#38;cauthor=true&#38;cauthor_uid=26800377">Linder I</a>, <a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=Kramer%20U%5BAuthor%5D&#38;cauthor=true&#38;cauthor_uid=26800377">Kramer U</a>, <a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=Epstein%20O%5BAuthor%5D&#38;cauthor=true&#38;cauthor_uid=26800377">Epstein O</a>, <a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=Menascu%20S%5BAuthor%5D&#38;cauthor=true&#38;cauthor_uid=26800377">Menascu S</a>, <a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=Nissenkorn%20A%5BAuthor%5D&#38;cauthor=true&#38;cauthor_uid=26800377">Nissenkorn A</a>, <a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=Yosef%20OB%5BAuthor%5D&#38;cauthor=true&#38;cauthor_uid=26800377">Yosef OB</a>, <a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=Hyman%20E%5BAuthor%5D&#38;cauthor=true&#38;cauthor_uid=26800377">Hyman E</a>, <a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=Granot%20D%5BAuthor%5D&#38;cauthor=true&#38;cauthor_uid=26800377">Granot D</a>, <a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=Dor%20M%5BAuthor%5D&#38;cauthor=true&#38;cauthor_uid=26800377">Dor M</a>, <a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=Lerman-Sagie%20T%5BAuthor%5D&#38;cauthor=true&#38;cauthor_uid=26800377">Lerman-Sagie T</a>, <a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=Ben-Zeev%20B%5BAuthor%5D&#38;cauthor=true&#38;cauthor_uid=26800377">Ben-Zeev B</a></p><h2>Highlights</h2><ul><li>•CBD-enriched medical cannabis is a promising treatment for intractable epilepsy.</li><li>•Only minor and infrequent side effects were reported.</li><li>•Epileptic encephalopathies respond better to CBD-enriched medical cannabis.</li></ul><h2>Abstract</h2><h3>Purpose</h3><p>To describe the experience of five Israeli pediatric epilepsy clinics treating children and adolescents diagnosed as having intractable epilepsy with a regimen of medical cannabis oil.</p><h3>Methods</h3><p>A retrospective study describing the effect of cannabidiol (CBD)-enriched medical cannabis on children with epilepsy. The cohort included 74 patients (age range 1–18 years) with intractable epilepsy resistant to &gt;7 antiepileptic drugs. Forty-nine (66%) also failed a ketogenic diet, vagal nerve stimulator implantation, or both. They all started medical cannabis oil treatment between 2–11/2014 and were treated for at least 3 months (average 6 months). The selected formula contained CBD and tetrahydrocannabinol at a ratio of 20:1 dissolved in olive oil. The CBD dose ranged from 1 to 20 mg/kg/d. Seizure frequency was assessed by parental report during clinical visits.</p><h3>Results</h3><p>CBD treatment yielded a significant positive effect on seizure load. Most of the children (66/74, 89%) reported reduction in seizure frequency: 13 (18%) reported 75–100% reduction, 25 (34%) reported 50–75% reduction, 9 (12%) reported 25–50% reduction, and 19 (26%) reported &lt;25% reduction. Five (7%) patients reported aggravation of seizures which led to CBD withdrawal. In addition, we observed improvement in behavior and alertness, language, communication, motor skills and sleep. Adverse reactions included somnolence, fatigue, gastrointestinal disturbances and irritability leading to withdrawal of cannabis use in 5 patients.</p><h3>Conclusions</h3><p>The results of this multicenter study on CBD treatment for intractable epilepsy in a population of children and adolescents are highly promising. Further prospective, well-designed clinical trials using enriched CBD medical cannabis are warranted.</p><p>Article available here on <a href="http://www.ncbi.nlm.nih.gov/pubmed/26800377">Pubmed</a>, full article <a href="https://secure.jbs.elsevierhealth.com/action/ecommerce?addToCart=true&#38;offerId=12%2C10.1016%2Fj.seizure.2016.01.004&#38;backUri=%2Farticle%2FS1059-1311%2816%2900005-4%2Fabstract&#38;code=yseiz-site">available for purchase here.</a></p></article>
      </section>
    </main>
    <footer class="astro-5AYKG27L">
  <div class="astro-5AYKG27L">

  </div>
</footer>


  
</body>


</html>